—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback